Posted by CaptainAmerica1967 on November 28, 2011, at 22:28:53
I've been following the company Alkermes for a couple of weeks as I had great success with buprenorphine for treatment resistant depression with generalized anxiety via it's kappa "antagonism/blocking" receptor effects (my best hypothesis based on having had other morphine related medications in either the hospital or ER; mu receptor opioid agonists like Vicoden's receptor effect and Demerol's kappa opioid "agnonist" receptor effect and now the company Alkermes has Alkermes 5461 (buprenorphine plus ?) going into phase II (http://www.alkermes.com/Research-and-Development/Pipeline) for treatment resistant depression as well as for cocaine addiction.
Alkermes 5461 is buprenorphine plus either a new opioid blocker like naltrexone or it may be Low Dose Naltrexone which normalized endorphin levels and prevents addiction to the buprenorphine and Alkermes owns the long acting liquid naltrexone Vivitrol so my guess is maybe the second component of AlKS 5461 is naltrexone, but Alkermes might have another chemical in development. Anyone have any ideas to the second component? http://investor.alkermes.com/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=1574033&highlight=
poster:CaptainAmerica1967
thread:1003842
URL: http://www.dr-bob.org/babble/20111120/msgs/1003842.html